Dexcom proposes $1.0B convertible notes due 2028; plans $250M share buyback

DEXCOM INC

Offering $1.0B aggregate principal of Convertible Senior Notes due 2028, with option for up to $150M additional.
Interest semi-annual; maturity May 15, 2028; convertible upon conditions prior to Feb 2028, freely thereafter.
Concurrent repurchase of up to $250M of common stock in privately negotiated transactions via initial purchasers.
Net proceeds also for capital expenditures, working capital, corporate purposes, potential acquisitions.
Plans capped call transactions to reduce dilution on conversion; cap price to be determined at pricing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.